Want to see GB:SAR full AI Analyst Report?
SAR Stock Chart & Stats
22.00 p
0.00 p(0.00%)
At close: 4:00 PM EDT
22.00 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range9.50 p - 29.00 p
Previous CloseN/A
Volume96.80K
Average Volume (3M)619.72K
Market Cap
£30.48M
Enterprise Value28.00M
Total Cash (Recent Filing)£2.49M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding138,565,170
10 Day Avg. Volume1,134,615
30 Day Avg. Volume619,716
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA lack of reported debt materially lowers financial risk and preserves flexibility to pursue R&D and licensing discussions. Over a multi-month horizon this reduces insolvency risk, improves negotiating leverage for partnerships, and limits fixed interest burdens on future cash flows.
Specialized Kinase Drug PlatformFocused expertise in TYK2/JAK kinase inhibition creates a durable scientific niche and clearer go-to-market rationale for autoimmune/inflammatory indications. Specialization increases technical credibility with larger partners and supports targeted out-licensing opportunities over the medium term.
Partner/licensing-focused Business ModelA partnering/licensing model is capital-efficient for small biotech: it concentrates value creation in R&D and monetizes via upfronts, milestones, and royalties. Structurally this reduces dependence on commercial infrastructure and aligns incentives with larger pharma acquirers over months to years.
Bears Say
Pre-revenue With Persistent LossesBeing pre-revenue with sustained operating losses means the company cannot self-fund R&D. Over a 2-6 month horizon this structural profitability gap forces continued external financing, raising dilution risk and constraining long-term strategic flexibility absent partner deals.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow creates an ongoing funding requirement to maintain programs. Structurally this increases reliance on equity or deal financing, risks interruption of development timelines, and pressures management to prioritize near-term cash raises over long-term value creation.
Very Small Team And Volatile Equity BaseA tiny employee base and a small, volatile equity position limit internal capacity to advance multiple programs concurrently and raise execution risk. Structurally, this increases dependence on CROs and partners and amplifies funding and governance vulnerability over the medium term.
Sareum Holdings News
SAR FAQ
What was Sareum Holdings PLC’s price range in the past 12 months?
Sareum Holdings PLC lowest share price was 9.50 p and its highest was 29.00 p in the past 12 months.
What is Sareum Holdings PLC’s market cap?
Sareum Holdings PLC’s market cap is £30.48M.
When is Sareum Holdings PLC’s upcoming earnings report date?
Sareum Holdings PLC’s upcoming earnings report date is Oct 26, 2026 which is in 90 days.
How were Sareum Holdings PLC’s earnings last quarter?
Sareum Holdings PLC released its earnings results on Mar 12, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.
Is Sareum Holdings PLC overvalued?
According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued.
Does Sareum Holdings PLC pay dividends?
Sareum Holdings PLC does not currently pay dividends.
What is Sareum Holdings PLC’s EPS estimate?
Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sareum Holdings PLC have?
Sareum Holdings PLC has 138,565,170 shares outstanding.
What happened to Sareum Holdings PLC’s price movement after its last earnings report?
Sareum Holdings PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Sareum Holdings PLC?
Currently, no hedge funds are holding shares in GB:SAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sareum Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.24%
Trailing 12-Months
Company Description
Sareum Holdings PLC
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.
Technical Analysis
ImmuPharma
―
Fusion Antibodies Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―